Pancreatic cancer tumor organoids exhibit subtype-specific differences in metabolic profiles

• Published in: Cancer & metabolism 2024-10, Vol.12 (1), p.28-13, Article 28
• Main Authors: Ali, Hassan A, Karasinska, Joanna M, Topham, James T, Johal, Danisha, Kalloger, Steve, Metcalfe, Andrew, Warren, Cassia S, Miyagi, Anthony, Tao, Lan V, Kevorkova, Maya, Chafe, Shawn C, McDonald, Paul C, Dedhar, Shoukat, Parker, Seth J, Renouf, Daniel J, Schaeffer, David F
• Format: Article
• Language: English
• Subjects: Analysis; Dextrose; Exhibitions; Gene expression; Genes; Genetic aspects; Genomics; Glucose; Glucose metabolism; Glycolysis; Medical equipment and supplies industry; Medical research; Medical test kit industry; Medicine, Experimental; Metabolites; Metastasis; MPC1; Organoids; OXPHOS; Pancreatic cancer; PDAC; PDAC tumor subtype; Physiological aspects; Scientific equipment and supplies industry
• ISSN: 2049-3002; 2049-3002
• DOI: 10.1186/s40170-024-00357-z

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive disease characterized by complex metabolic rewiring that enables growth in changing nutrient availability and oxygen conditions. Transcriptome-based prognostic PDAC tumor subtypes, known as 'basal-like' and 'classical' subtypes are associated with differences in metabolic gene expression including genes involved in glycolysis. Tumor subtype-specific metabolism phenotypes may provide new targets for treatment development in PDAC, but their functional relevance has not been fully elucidated. We aimed to investigate differences in metabolic profiles and transcriptomes in tumor models derived from patients with basal-like and classical tumors. Patient-derived organoids (PDOs) were established from tumor biopsies collected from patients with metastatic PDAC, including three PDOs from basal-like and five PDOs from classical tumors. Metabolic analyses included assessment of differences in metabolic activity using Seahorse Glycolysis and Mito Stress tests and C-glucose metabolites tracing analysis. In order to investigate the influence of mitochondrial pyruvate transport on metabolic differences, PDOs were treated with the mitochondrial pyruvate carrier 1 (MPC1) inhibitor UK-5099. Prognostic relevance of MPC1 was determined using a tumor tissue microarray (TMA) in resectable, and proteomics profiling in metastatic PDAC datasets. Whole genome and transcriptome sequencing, differential gene expression and gene set enrichment analyses were performed in PDOs. Metastatic PDAC PDOs showed subtype-specific differences in glycolysis and oxidative phosphorylation (OXPHOS). Basal-like tumor-derived PDOs had a lower baseline extracellular acidification rate, but higher glycolytic reserves and oxygen consumption rate (OCR) than classical tumor-derived PDOs. OCR difference was eliminated following treatment with UK-5099. In the C-glucose metabolites tracing experiment, a basal-like tumor PDO showed lower fractions of some M + 2 metabolites but higher sensitivity to UK-5099 mediated reduction in M + 2 metabolites than a classical tumor PDO. Protein level analyses revealed lower MPC1 protein levels in basal-like PDAC cases and association of low MPC1 levels with clinicopathologic parameters of tumor aggressiveness in PDAC. PDO differential gene expression analyses identified additional subtype-specific cellular pathways and potential disease outcome biomarkers. Our findings point to distinct metabolic profiles in PDA